Ollin Biosciences Emerges from Stealth with $100M to Advance Vision Therapies

Ollin Biosciences launched in September 2025 with $100 million in Series A funding to develop best-in-class therapies for vision-threatening diseases. The clinical-stage biopharmaceutical company focuses on in-licensing validated drug candidates with established regulatory pathways.

OLN324: Wet AMD & DME Treatment

Ollin's lead program, OLN324, targets wet age-related macular degeneration (wAMD) and diabetic macular edema (DME)—leading causes of vision loss in older and working-aged populations. Licensed from China-based Innovent Biologics, OLN324 is a high-potency VEGF/Ang2 bispecific antibody designed for higher molar dosing.

The drug offers key advantages over current treatments: it has approximately one-third the molecular weight of faricimab (Vabysmo), enabling delivery at higher molar doses for greater target coverage. OLN324 also demonstrates substantially higher anti-Ang2 potency compared to faricimab, potentially offering superior disease control and extended treatment durability.

The company completed enrollment of over 150 patients with wAMD or DME in the JADE study, a randomized, U.S.-based Phase 1b proof-of-concept trial comparing OLN324 versus faricimab. Topline results from this head-to-head comparison are expected in Q1 2026.

OLN102: Thyroid Eye Disease Therapy

OLN102 addresses thyroid eye disease (TED), affecting 25-50% of people with Graves' disease. This first-in-class TSHR/IGF-1R bispecific antibody treats both TED and the underlying Graves' disease by simultaneously inhibiting thyroid stimulating hormone receptor (TSHR) and insulin-like growth factor 1 receptor (IGF-1R).

Licensed from China-based VelaVigo, OLN102 may offer improved outcomes by targeting both disease pathways simultaneously, potentially reducing side effects while maintaining efficacy. The program is expected to enter clinical development in 2026.

Leadership & Strategy

Jason Ehrlich, M.D., Ph.D., serves as Chief Executive Officer, bringing extensive ophthalmology drug development experience from Genentech, where he contributed to faricimab's development. His background provides strategic insights for navigating regulatory challenges and competitive positioning.

The company's head-to-head JADE trial against faricimab provides direct comparative data for regulatory and commercial differentiation. In thyroid eye disease, current standard of care Tepezza (teprotumumab) targets only the IGF-1R pathway, while OLN102's dual-target approach may offer enhanced therapeutic benefits.

Market Opportunity

The global ophthalmology market is projected to reach $72.59 billion by 2034. Wet AMD and DME represent significant unmet needs, with current anti-VEGF therapies requiring frequent injections and showing durability limitations.

Ollin actively scouts globally for additional therapeutic opportunities beyond its current bispecific antibody programs. With substantial Series A funding and experienced leadership, the company is positioned to advance both lead programs through clinical development while building a broader pipeline of innovative therapies.